Novo Nordisk A/S (NYSE: NVO) — Company Overview, News & Financial Data
Novo Nordisk A/S specializes in diabetes care, advancing pharmaceutical products to improve outcomes for chronic conditions.
Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity management, rare blood and endocrine disorders, and cardiovascular conditions. Headquartered in Bagsvaerd, Denmark, the business researches, develops, manufactures, and markets biological pharmaceuticals and advanced drug delivery systems worldwide. Core therapy areas focus on glucagon-like peptide-1 receptor agonists, human and modern insulins, and hormone replacement therapies. Operations span research facilities, manufacturing sites, and commercial subsidiaries across Europe, North America, Asia-Pacific, and Latin America, supplying pharmaceutical products to patients in approximately 170 countries.
Snapshot
Operations
Products and/or services of Novo Nordisk A/S
- Diabetes Care Pharmaceuticals: Development, manufacturing, and distribution of human insulins, modern insulin analogues, and glucagon-like peptide-1 receptor agonist therapies for type 1 and type 2 diabetes management. Products are distributed globally across major international pharmaceutical markets.
- Obesity Care Treatments: Production and commercialization of prescription biological medications designed for chronic weight management and weight-related comorbidities. Therapies target metabolic pathways to support long-term weight reduction and maintenance in adult and pediatric patient populations.
- Rare Disease Therapies: Formulation and distribution of specialized biopharmaceuticals treating rare blood disorders such as hemophilia, as well as rare endocrine disorders including growth hormone deficiency. Treatments address specific genetic and hormonal deficiencies.
- Cardiovascular and Metabolic Disease Pipeline: Clinical development and commercial delivery of therapeutic solutions addressing cardiovascular diseases, chronic kidney diseases, and metabolic dysfunction-associated steatohepatitis. Research efforts focus on reducing organ damage and improving cardiometabolic outcomes.
- Drug Delivery Systems and Devices: Design and manufacture of administration hardware, including prefilled insulin pens, durable injection pens, fine-gauge needles, and connected smart injection devices. These products facilitate precise dosage control and improved patient compliance.
- Contract Manufacturing and Partnering Services: Provision of biomanufacturing capacities, pharmaceutical formulation services, and strategic clinical research collaborations. Operations utilize specialized production facilities to supply active pharmaceutical ingredients and finished dosage forms to global healthcare partners.
Novo Nordisk A/S executive team
- Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board
- Maziar Mike DoustdarPresident, CEO & Member of the Management Board
- Martin Holst LangeEVP of R&D, Chief Scientific Officer and Member of the Management Board
- Tania SabroeEVP of People, Organisation and Corporate Affairs & Member of Management Board
- Thilde Hummel BogebjergExecutive VP of Enterprise IT & Quality and Member of Management Board
- John F. KuckelmanSVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board
- Emil Kongshoej LarsenEVP of International Operations & Member of Management Board
- Elin JagerSVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board
- Jamey MillarExecutive VP of US Operations & Member of Management Board
- Hong ChowExecutive VP of Product & Portfolio Strategy and Member of Management Board